Series A · Biotech · London, United Kingdom · 11–50 employees
Inoviv is a London-based biotechnology company specializing in targeted proteomics to support pharmaceutical companies with biomarker test development, offering multiplexed and quantitative LC-MS proteomics services to accelerate drug discovery and development; with significant funding from Hoxton Ventures and Foresight Group, it has expanded its product offerings and global reach, demonstrating strong revenue growth from £150k in 2022 to over £1 million in 2023.
No open roles listed right now.